Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Main Inclusion Criteria:

* Signed informed consent prior to any procedures
* Phase Ib part: Adult patients with advanced melanoma, endometrial carcinoma, pancreatic or TNBC, with measurable or non-measurable disease who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists.
* Phase II part: Adult patients with advanced solid tumors who have received standard therapy (no more than 3 prior lines of treatment) or are intolerant of standard therapy, have progressed following their last prior therapy, and fit into one of the following groups:

  * Group 1: TNBC who did not receive prior anti-PD-1/PD-L1 treatment
  * Group 2: Pancreatic adenocarcinoma who did not receive prior anti-PD-1/PD-L1 treatment
  * Group 3: Endometrial carcinoma who did not receive prior anti-PD-1/PD-L1 treatment
  * Group 4: Melanoma who progressed on prior anti-PD-1/PD-L1 treatment.

Main Exclusion Criteria:

* Patients with the following:

  * Symptomatic central nervous system (CNS) metastases or those requiring local CNS-directed therapy.
  * Abnormal liver, renal, or blood lab values.
  * Impaired cardiac function or clinically significant cardiac disease.
  * Active autoimmune disease or documented autoimmune disease within 3 years of screening.
  * Active infection requiring antibiotic therapy.
  * Known HIV, active hepatitis B or C virus.
  * Concurrent malignant disease.
* Patients who received systemic anticancer therapy, major surgery, or radiotherapy within 2 weeks of study treatment, or live vaccines within 4 weeks of study treatment.
* Patients requiring chronic treatment with systemic steroid therapy or any immunosuppressive therapy.
* Patients who used hematopoietic colony-stimulating growth factors within 2 weeks of study treatment.